Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

Abstract Background Eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody recently approved in the United States for preventive treatment of migraine in adults, was found to be well tolerated in double-blind, placebo-controlled studies in patients with episodic and chronic migrain...

Full description

Bibliographic Details
Main Authors: David Kudrow, Roger K. Cady, Brent Allan, Susan M. Pederson, Joe Hirman, Lahar R. Mehta, Barbara A. Schaeffler
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Neurology
Subjects:
Eptinezumab
Chronic migraine
Effectiveness
Safety
Immunogenicity
Online Access:https://doi.org/10.1186/s12883-021-02123-w

Similar Items

Similar Items